US20100137404A1 - Compositions and Methods for Altering Gene Expression - Google Patents

Abstract

Compositions and methods for regulating gene expression in a growing animal are disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
• This application claims priority to U.S. Provisional Application No. 60/891,171, filed on Feb. 22, 2007, the contents of which are incorporated herein by reference.
FIELD OF THE INVENTION
• The present invention relates to compositions and methods regulating gene expression or transcription in a growing animal.
BACKGROUND OF THE INVENTION
• Commercially available canine and feline foods include compositions specially formulated to address many different nutritional needs. These include, for example, formulations designed for different breed types, sizes and body conditions. They also include formulations designed to address the nutritional needs of animals in the different stages of their life cycle. Typically, these stages include the growth, adult and senior stages of life. For example, U.S. Pat. No. 5,851,573 discloses a pet food composition for large breed puppies; U.S. Pat. No. 6,426,100 discloses compositions to provide improved bone modeling and chondrocyte functioning in growing animals; U.S. Pat. No. 6,582,752 discloses gender specific puppy food. Despite the availability of such pet food formulations, however, the need remains for the development of additional formulations comprising innovative ingredients and nutrients designed to enhance the development of growing animals.
• It is known in the art that certain nutrients have an effect on gene expression. Nutrigenomics is the study of such a relationship. Despite what is already known, there is a need to develop compositions and methods which may positively influence gene expression of an animal.
SUMMARY OF THE INVENTION
• In certain aspects, the present invention relates to compositions that are useful to enhance the development of a growing animal. Particularly, the compositions of the present invention comprise one or more nutrients or bioactive substances that can enhance neurologic development, bone and joint health, immune function, and promote healthy body composition in a growing animal. In certain embodiments, the nutrients and bioactive substances include, but are not limited to, fatty acids, antioxidants, essential nutrients, amino acids, minerals and trace elements, vitamins and vitamin-like substances. Other aspects of the invention relate to methods to enhance the development of a growing animal comprising administration of effective amounts of the compositions of the present invention directly to a growing animal or to the dam of said animal while the animal is in utero or is a nursling.
• Thus, in one aspect, the present invention includes Composition 1.0, a pet food composition comprising:
• about 5 to about 70% protein,
• about 0.5 to about 1.6% methionine,
• about 50 to about 200 ppm manganese,
• about 0.1 to about 0.5% DHA,
• about 0.1 to about 0.7% EPA,
• about 1200 to about 7500 ppm choline,
• about 1000 to about 2000 ppm taurine,
• about 2.5 to about 6% linoleic acid,
• about 1 to about 3% total n-3 fatty acids,
• about 50 to about 1200 IU/kg vitamin E,
• about 50 to about 500 ppm vitamin C,
• about 50 to about 500 ppm carnitine, and
• about 2.5 to about 7 g lysine/1000 kcal.
• The preset invention also includes the following compositions:
• 1.1 Composition 1.0 comprising:
• • 0 to about 90% by weight of carbohydrates;
  • about 20% to about 60% by weight of protein;
  • about 2% to about 50% by weight of fat;
  • about 0.1% to about 20%, by weight of total dietary fiber; and
  • 0 to about 15% by weight of vitamins, minerals, and other nutrients in varying percentages which support the nutritional needs of the animal.
    1.2 Composition 1.0 or 1.1 comprising about 5% to about 55%, by weight of carbohydrates;
    1.3 Any of the preceding compositions comprising about 20% to about 50%, by weight of protein, e.g., about 22% to about 50%;
    1.4 Any of the preceding compositions comprising about 5% to about 40%, by weight of fat, e.g., e.g., at least about 8% or about 9% to about 40% fat;
    1.5 Any of the preceding compositions comprising about 1% to about 11%, by weight of total dietary fiber;
    1.6 Any of the preceding compositions comprising about 0.1% to about 0.4% DHA, e.g., about 0.5%; 61.7 Any of the preceding compositions comprising about 200 IU/kg to about 1200 IU/kg Vitamin E, e.g., about 200 IU/kg to about 1000 IU/kg;
    1.9 Any of the preceding compositions comprising about 100 ppm to about 500 ppm carnitine, e.g., about 200 to about 400, or about 300 ppm;
    1.10 Any of the preceding compositions comprising about 2.5 g/1000 kcal to about 7 g/1000 kcal lysine;
    1.11 Any of the preceding compositions comprising about 2500 ppm to about 7500 ppm choline, e.g., about 3000, about 3500, about 4000, about 4500, about 4600, about 4625, about 4650, about 4700, about 4800, or about 6000 ppm;
    1.12 Any of the preceding compositions comprising about 0.1% to about 0.6% EPA;
    1.13 Any of the preceding compositions comprising about 50 ppm to about 150 ppm manganese; and
    1.14 Any of the preceding compositions comprising about 0.8% to about 1.6% methionine.
• In another aspect, the invention relates to methods to cause a beneficial modification in gene expression in an animal, specifically, down regulation in expression of a gene or genes associated with an undesirable biological condition or pathway or disease state and/or up regulation in expression of a gene or genes associated with a desired biological condition or pathway or which may have a positive or preventive effect on a disease state for any one or more biological conditions, pathways or disease states and genes described in Tables 2-15, comprising administering an effective amount of a composition of according to any one of compositions 1.0-1.14 to an animal, either directly to the animal or to the dam while the animal is in utero.
• In another aspect, the invention is directed to Method 2.0, a method to regulate gene expression in a canine comprising administering to the canine any one of compositions the compositions of the present invention, e.g., compositions 1.0-1.14.
• The present invention also includes the following methods:
• • 2.1 Of method 2.0 wherein the canine is a puppy.
  • 2.2 Of method 2.0 or 2.1 wherein the canine is born of a dam fed any one of compositions 1.0-1.14 during pregnancy.
  • 2.3 Of method 2.2 wherein the puppy is in utero.
  • 2.4 Of method 2.2 wherein the dam is fed any one of compositions 1.0-1.14 prior to pregnancy.
  • 2.5 Of method 2.2 or 2.4 wherein the dam is fed any one of compositions 1.0-1.14 for a majority of the pregnancy duration.
  • 2.6 Of any one of methods 2.2-2.5 wherein the dam is fed compositions consisting essentially of any one of compositions 1.0-1.14 prior to and during pregnancy.
  • 2.7 Of any one of the preceding methods wherein the puppy is fed any one of compositions 1.0-1.14 prior to weaning, e.g., while still a nursling.
  • 2.8 Of any one of the preceding methods wherein the puppy is fed any one of compositions 1.0-1.14 post weaning.
  • 2.9 Of method 2.8 wherein the puppy is fed food compositions consisting of any one of compositions 1.0-1.14.
  • 2.10 Of any one of the preceding methods wherein an effective amount of the composition is administered to the canine.
  • 2.11 Of any one of the preceding methods wherein the composition is administered to the canine for an effective amount of time.
  • 2.12 Of method 2.11 wherein the composition is administered to the canine for at least one year post partum or one year post weaning.
  • 2.13 Of any one of the preceding method wherein the gene is selected from those listed in Tables 2-15.
• In a further aspects, the invention relates to the use of any of the formulae of the present invention in the manufacture of a composition to modify gene expression in an animal as described herein.
• Other features and advantages of the present invention will be understood by reference to the detailed description of the examples that follow.
DETAILED DESCRIPTION OF THE INVENTION
• It is contemplated that the invention described herein is not limited to the particular methodology, protocols, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention in any way.
• Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, all references cited herein are hereby incorporated by reference in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
• As used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise.
• The present invention relates to any animal, preferably a mammal, more preferably a companion animal. The term “companion animal” refers to any animal that lives in close association with humans and includes, but is not limited to, canines and felines of any breed. It is contemplated herein, however, that any animal whose diet may be controlled by humans may benefit from feeding the formulations disclosed herein. These animals may include, for example, domesticated farm animals (e.g., cattle, horses, swine, etc.) as well as undomesticated animals held in captivity, e.g., in zoological parks and the like. Preferred animals include canines, e.g., dogs, including growing dogs, e.g., puppies.
• “Beneficial modification in the expression of genes” as used herein includes, e.g., down regulation of genes expressing proteins associated with disease states and/or up regulation of genes expressing proteins which have a beneficial or healthful effect as compared to appropriate controls, as may be determined using conventional methods, e.g., by microarray (e.g., Affymetrix gene chip) techniques familiar to one of skill in the art. Further, one of skill in the art is familiar with the known associations between diseases and specific genes as those listed in the tables provided hereinbelow such that it is understood whether an increase or decrease in expression of a particular gene is desirable.
• The “growth” life stage of an animal refers to the period from birth or weaning (approximately 8 weeks of age) to about 1 year of age or beyond, depending on the species and breed of the animal.
• As used herein, the term “puppy” refers to an immature canine, typically between the ages of birth and 12 months.
• “Essential amino acids” as used herein refers to those amino acids that cannot be synthesized de novo by an organism and thus must be supplied in the diet. It is understood by one of skill in the art that the essential amino acids varies from species to species, depending upon the organism's metabolism. For example, it is generally understood that the essential amino acids for dogs and cats (and humans), are phenylalanine, leucine, methionine, lysine, isoleucine, valine, threonine, tryptophan, histidine and arginine.
• As understood by one of skill in the art, a “limiting amino acid” refers to an amino acid which if present in insufficient quantities in a diet, results in the limitation in usefulness of other essential amino acids, even if the other essential amino acids are present in otherwise large enough quantities. Lysine is the limiting essential amino acid in the compositions disclosed herein. Thus, the remaining essential amino acids are quantitatively formulated or “balanced” in relationship to the amount of lysine determined critical to affect the desired biological result. As used herein, “balanced amino acids” refers to the relationship of the essential amino acid lysine to energy to assure optimal animal growth and development.
• “Essential nutrients” as used herein refers to nutrients required for normal body functioning that cannot be synthesized by the body. Categories of essential nutrient include vitamin dietary minerals, fatty acid, and amino acid. It is understood by one of skill in the art that the nutrients deemed essential varies from species to species, depending upon the organism's metabolism. For example, essential nutrients for dogs and cats include Vitamins A, D, E, K, B1, B6 B12, riboflavin, niacin, pantothenic acid, folic acid, calcium, phosphorous, magnesium, sodium, potassium, chlorine, iron, copper, zinc, manganese, selenium and iodine. Choline, generally regarded as a B complex vitamin, may be included among the semi-essential nutrients. In addition, taurine, while technically not an amino acid but a derivative of cysteine, is an essential nutrient for cats.
• Carnitine, also known as L-carnitine, (levocarnitine) is a quaternary ammonium compound synthesized from the amino acids lysine and methionine and is responsible for the transport of fatty acids from the cytosol into the mitochondria.
• Without being limited to any theories or particular modes of action, the present invention is based on the surprising discovery that the addition of certain ingredients to pet food compositions and administration of these compositions to animals can enhance the development of a growing animal. For example, data indicate that animals fed the compositions of the present invention (or those whose dams were fed the compositions during gestation and prior to weaning but continued throughout growth of their litters), demonstrate enhanced neurologic development, bone and joint health, immune function, and have overall healthier body composition. Interestingly, microarray data also indicate a differential change in gene expression in these animals compared to controls which is generally reflective of a beneficial modification (i.e., up or down regulation) in the expression of many genes associated with biological processes including those involved in growth and development. Thus, in one aspect, the invention relates to compositions and methods to enhance the development of a growing animal as described in detail herein.
• As contemplated herein, the compositions of the present invention comprise nutritionally complete and balanced animal feed compositions. Such compositions include, among other nutrients and ingredients, recommended healthful amounts of protein, carbohydrate and fat. “Nutritionally complete and balanced animal feed compositions”, as well as nutrients and ingredients suitable for animal feed compositions, and recommended amounts thereof, are familiar to one of skill in the art (see, for example, National Research Council, 2006 Nutritional Requirements for Dogs and Cats, National Academy Press, Washington D.C. or the Official Publication of the Association of American Feed Control Officials, Inc. Nutrient Requirements for Dogs and Cats 2006).
• It is contemplated herein that the compositions disclosed herein may also comprise antioxidants, additives, stabilizers, thickeners, flavorants, palatability enhancers and colorants in amounts and combinations familiar to one of skill in the art. “Antioxidants” refers to a substance that is capable of reacting with or decreasing the production of free radicals and neutralizing them. Examples include, but are not limited to, beta-carotene, selenium, coenzyme Q10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, vitamin E, vitamin D, vitamin C, flavanoids, anthocyanindins, and lipoic acid.
• While foods of any consistency or moisture content are contemplated, preferably the compositions of the present invention may be, for example, a wet, semi-dry, or dry animal food composition. “Wet” food refers to food which is sold in cans or foil bags and has a moisture content of about 70 to about a 90%. “Dry” food refers to compositions with about 5 to about 15% moisture content and is often manufactured in the form of small bits or kibbles. Semi-dry compositions refers to food which has a moisture content greater than dry foods, but less than wet foods. Also contemplated herein are compositions of intermediate moisture consistency and those that may comprise components of various consistency as well as components that may include more than one consistency, for example, soft, chewy meat-like particles as well as kibble having an outer cereal component and an inner cream component as described in, e.g., U.S. Pat. No. 6,517,877.
• Various processes for manufacturing and packaging the compositions of the present invention may be employed and are familiar to one of skill in the art.
• It is also contemplated herein that the methods of the present invention include methods to cause a beneficial modification in gene expression in an animal, specifically, down regulation in expression of a gene or genes associated with an undesirable biological condition or pathway or disease state and/or up regulation in expression of a gene or genes associated with a desired biological condition or pathway or which may have a positive or preventive effect on a disease state, as the case may be, for any one or more biological conditions, pathways or disease states and genes described in Tables 14-27, comprising administering an effective amount of a composition of the present invention to the animal, either directly to the animal or to the dam while the animal is in utero. Indeed, as discussed in Examples 7 and 8 here-in-below, by effecting the animal at the genomic level, the administration of the compositions of the present invention, either directly to the animal or to the dam while the animal is in utero, may have beneficial, even prophylatic, health effects on the animal by effecting the expression of any one or more genes listed in Tables 14-27. For example, the administration of an effective amount of a composition of the present invention to an animal may enhance bone and joint health in the animal by causing the down regulation in genes associated with cartilage and joint damage associated with arthritis, e.g. interleukin 1-beta, fibronectin, lactoransferrin, etc. (see Table 14).
• It is contemplated herein that the compositions of the present invention may be administered to an animal alone as a complete nutritionally balanced diet, or in conjunction with dietary supplements, vitamins and/or other nutritionally beneficial agents familiar to one of skill in the art, as part of an overall wellness program for the animal. Compositions of the invention may also be useful as a veterinary therapeutic product. As such, the compositions may optionally contain a carrier, diluent, or an excipient, the suitability of which for the intended use being familiar to one of skill in the art.
• It is also contemplated that, in addition to administering the compositions disclosed herein directly to a growing animal, e.g., to a growing puppy or kitten, the compositions may be administered to the dam of the animal while the animal is still in utero or while the animal is a nursling.
• The following examples further illustrate the present invention and are not intended to limit the invention. As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. It is understood that when formulations are described, they may be described in terms of their ingredients, as is common in the art, notwithstanding that these ingredients may react with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described.
• The following examples further describe and demonstrate illustrative embodiments within the scope of the present invention. The examples are given solely for illustration and are not to be construed as limitations of this invention as many variations are possible without departing from the spirit and scope thereof. Various modifications of the invention in addition to those shown and described herein should be apparent to those skilled in the art and are intended to fall within the appended claims.
• Except to the extent stated otherwise, all percentages used in this specification are weight percentages on a dry matter basis. The phrase “dry matter basis” means the component concentration in the composition after any moisture in the composition is removed.
EXAMPLES Example 1 Canine Genetic Effects: Conception to One Year of Age
• In order to characterize the genotypic effects of feeding a composition formulated to enhance the development of a growing animal, an experiment is performed to identify changes in gene expression in puppies at one year of age from dams fed the compositions disclosed in Table 1.

• TABLE 1
  Average of analyzed nutrient profiles of foods utilized in the study

  	Nutrients, 100%
  	Dry Matter Basis	Composition H	Composition P

  	Moisture, %	6.09	7.44
  	Crude Protein, %	29.4	27.9
  	Fat, %	17.6	14.2
  	Ca, %	1.43	1.46
  	P, %	1.2	0.96
  	EPA, %	0.31	<0.01
  	DHA %	0.19	0.01
  	Linoleic Acid, %	3.8	2.14
  	Total n-3 fatty acids, %	1.4	0.19
  	Total n-6 fatty acids, %	3.7	2.6
  	Taurine, %	0.14	0.08
  	Carnitine, ppm	312.1	No analysis
  	Methionine, %	1.3	0.52
  	Cystine, %	0.4	0.39
  	Manganese, %	94.5	64
  	Vitamin E, IU/kg	816	43.8
  	Vitamin C, ppm	168.6	<10
  	Choline, ppm	4876	No analysis

• Composition P is a commercially available dog food. Composition H is an experimental dog food composition.
• Dams are fed either Composition H or Composition P for at least 10 days prior to conception. Dams are maintained in group lodging until confirmed pregnant via palpation, and are then moved to maternity lodging. Puppies from dams are kept on the same foods fed to the dams until one year of age (including pre-weaning and post-weaning period). Blood samples are then taken from the puppies and mRNA isolated according to conventional methods. Microarray assays are performed using the Affymetrix Canine-2 gene chip according to conventional methods.
• The tables below show the genes grouped by function and the direction of expression, wherein up regulation in Composition H (“H”) vs Composition P (“P”) demonstrates increased gene expression in Composition H fed puppies compared to Composition P fed puppies. Similarly, down regulation of a gene in the Composition H fed puppies vs Composition P fed puppies represents decreased gene expression in puppies fed Composition H relative to those fed Composition P.

• TABLE 2
  Genes associated with arthritis/inflammation
  relevant to bone and joints

  		Direction of
  		expression
  Annotation	Probe	H vs P
  Interleukin 1-beta	CfaAffx.11741.1.S1_s_at	down
  Fibronectin	Cfa.3707.1.A1_s_at	down
  v-fos FBJ murine osteo-	Cfa.9039.1.A1_at	down
  sarcoma viral oncogene
  homolog
  dual specificity phosphatase 1	CfaAffx.25714.1.S1_s_at	down
  Lactotransferrin	CfaAffx.21286.1.S1_s_at	down
  compliment component 5a	CfaAffx.7180.1.S1_s_at	down
  receptor
  xanthine dehydrogenase	CfaAffx.9452.1.S1_s_at	down
  Secreted phoshoprotein 1	CfaAffx.15042.1.S1_s_at	down

• TABLE 3
  Genes associated with DNA replication and repair

  		Direction of
  		expression
  Annotation	Probe	H vs P
  DNA fragmentation
  Interleukin 1-beta	CfaAffx.11741.1.S1_s_at	down
  Fibronectin	Cfa.3707.1.A1_s_at	down
  Neuroregulin 1	CfaAffx.10523.1.S1_s_at	down
  Dual specificity phosphatase 1	CfaAffx.25714.1.S1_s_at	down
  Cell death-inducing DFFA-	CfaAffx.28752.1.S1_at	down
  like effector a
  Proper DNA processing
  control
  Budding uninhibited by	Cfa.1559.1.A1_at	up
  benzimidazoles 1 homolog
  Topoisomerase II alpha	Cfa.18946.1.S1_s_at	up
  Kinetochore associated 2	Cfa.3066.1.S1_s_at	up
  Claspin homolog	CfaAffx.6235.1.S1_s_at	up
  Cyclin B1	CfaAffx.12419.1.S1_s_at	up
  Cyclin B2	Cfa.11939.1.A1_s_at	up
  Human chromosome	CfaAffx.25509.1.S1_at	up
  condensation protein G
  Leucine zipper protein 5	CfaAffx.8781.1.S1_s_at	up
  Kinesin family member 23	Cfa.15293.1.A1_at	up
  Flap structure specific	Cfa.1854.1.A1_at	up
  endonuclease 1

• TABLE 4
  Genes associated with cancer

  		Direction of
  		expression
  Annotation	Probe	H vs P
  Interleukin 1-beta	CfaAffx.11741.1.S1_s_at	down
  Fibronectin	Cfa.3707.1.A1_s_at	down
  v-fos FBJ murine osteosarcoma viral oncogene	Cfa.9039.1.A1_at	down
  homolog
  dual specificity phosphatase 1	CfaAffx.25714.1.S1_s_at	down
  compliment component 5a receptor	CfaAffx.7180.1.S1_s_at	down
  xanthine dehydrogenase	CfaAffx.9452.1.S1_s_at	down
  cellular repressor of E1A-stimulated genes 1	Cfa.10558.3.A1_at	down
  chondroitin sulfate proteoglycan 2	CfaAffx.13597.1.S1_s_at	down
  transcobalamin II, mycrocytic anemia	CfaAffx.19852.1.S1_s_at	down
  serpin peptidase inhibitor, clade B member 10	CfaAffx.1043.1.S1_s_at	down
  adenomatosis polyposis coli down-regulated 1	CfaAffx.28621.1.S1_at	down
  six membrane epithelial antigen of the prostate 2	Cfa.1933.1.S1_at	down
  alanyl aminopeptidase	Cfa.3774.1.A1_s_at	down
  Cancer susceptibility candidate 5	Cfa.1126.1.S1_at	up
  Paternally expressed 3	Cfa.4482.1.S1_at	up
  Topoisomerase II alpha	Cfa.18946.1.S1_s_at	up
  Tubulin alpha 6	CfaAffx.13667.1.S1_at	up
  Cyclin B1	CfaAffx.12419.1.S1_s_at	up
  Cell division cycle associated 1	CfaAffx.20529.1.S1_at	up
  Cell division cycle 2	CfaAffx.20006.1.S1_at	up
  Ribonucleotide reductase M2 polypeptide	CfaAffx.6059.1.S1_at	up
  Breast cancer anti-estrogen resistance 3	Cfa.651.1.S1_at	up
  Tumor necrosis factor receptor superfamily	CfaAffx.28790.1.S1_at	up
  member 17
  Protein kinase C, iota	CfaAffx.22822.1.S1_s_at	up

• TABLE 5
  Genes associated with cell compromise

  		Direction of
  		expression
  Annotation	Probe	H vs P
  Interleukin 1-beta	CfaAffx.11741.1.S1_s_at	down
  Fibronectin	Cfa.3707.1.A1_s_at	down
  Neuroregulin 1	CfaAffx.10523.1.S1_s_at	down
  v-fos FBJ murine osteo-	Cfa.9039.1.A1_at	down
  sarcoma viral oncogene
  homolog
  dual specificity phosphatase 1	CfaAffx.25714.1.S1_s_at	down
  compliment component 5a	CfaAffx.7180.1.S1_s_at	down
  receptor
  xanthine dehydrogenase	CfaAffx.9452.1.S1_s_at	down
  Macrophage receptor with	Cfa.15713.1.A1_s_at	down
  collagenous structure
  Cyclin B1	CfaAffx.12419.1.S1_s_at	up
  Cell division cycle 2	CfaAffx.20006.1.S1_at	up
  Hemoglobin epsilon 1	CfaAffx.10240.1.S1_s_at	up
  Protein kinase C, iota	CfaAffx.22822.1.S1_s_at	up

• TABLE 6
  Genes associated with cellular assembly

  		Direction of
  		expression
  Annotation	Probe	H vs P
  Interleukin 1-beta	CfaAffx.11741.1.S1_s_at	down
  Fibronectin	Cfa.3707.1.A1_s_at	down
  Neuroregulin 1	CfaAffx.10523.1.S1_s_at	down
  chondroitin sulfate	CfaAffx.13597.1.S1_s_at	down
  proteoglycan 2
  cholinergic receptor,	Cfa.8414.1.A1_s_at	down
  muscarinic 3
  xanthine dehydrogenase	CfaAffx.9452.1.S1_s_at	down
  Macrophage receptor with	Cfa.15713.1.A1_s_at	down
  collagenous structure
  Cyclin B1	CfaAffx.12419.1.S1_s_at	up
  Cell division cycle 2	CfaAffx.20006.1.S1_at	up
  Leucine zipper protein 5	CfaAffx.8781.1.S1_s_at	up
  Protein kinase C, iota	CfaAffx.22822.1.S1_s_at	up
  Kinesin family member 23	Cfa.15293.1.A1_at	up
  Budding uninhibited by	Cfa.1559.1.A1_at	up
  benzimidazoles 1 homolog
  Cyclin B2	Cfa.11939.1.A1_s_at	up
  Topoisomerase II alpha	Cfa.18946.1.S1_s_at	up
  Kinetochore associated 2	Cfa.3066.1.S1_s_at	up
  Cell division cycle	CfaAffx.20529.1.S1_at	up
  associated 1
  Human chromosome	CfaAffx.25509.1.S1_at	up
  condensation protein G
  Kinesin family member 11	CfaAffx.12118.1.S1_s_at	up
  A kinase (PRKA) anchor	Cfa.10574.1.A1_at	up
  protein 2
  thymopioten	Cfa.18367.2.S1_s_at	up

• TABLE 7
  Genes associated with cell cycle regulation

  		Direction of
  		expression
  Annotation	Probe	H vs P
  Interleukin 1-beta	CfaAffx.11741.1.S1_s_at	down
  Fibronectin	Cfa.3707.1.A1_s_at	down
  Neuroregulin 1	CfaAffx.10523.1.S1_s_at	down
  v-fos FBJ murine osteosarcoma viral oncogene	Cfa.9039.1.A1_at	down
  homolog
  cholinergic receptor, muscarinic 3	Cfa.8414.1.A1_s_at	down
  dual specificity phosphatase 1	CfaAffx.25714.1.S1_s_at	down
  cellular repressor of E1A-stimulated genes 1	Cfa.10558.3.A1_at	down
  Cyclin B1	CfaAffx.12419.1.S1_s_at	up
  Cell division cycle 2	CfaAffx.20006.1.S1_at	up
  Leucine zipper protein 5	CfaAffx.8781.1.S1_s_at	up
  centromere protein F, 350/400ka (mitosin)	CfaAffx.19534.1.S1_at	up
  Breast cancer anti-estrogen resistance 3	Cfa.651.1.S1_at	up
  Budding uninhibited by benzimidazoles 1	Cfa.1559.1.A1_at	up
  homolog
  Cyclin B2	Cfa.11939.1.A1_s_at	up
  Topoisomerase II alpha	Cfa.18946.1.S1_s_at	up
  Kinetochore associated 2	Cfa.3066.1.S1_s_at	up
  Cell division cycle associated 1	CfaAffx.20529.1.S1_at	up
  Human chromosome condensation protein G	CfaAffx.25509.1.S1_at	up
  Kinesin family member 11	CfaAffx.12118.1.S1_s_at	up
  thymopioten	Cfa.18367.2.S1_s_at	up

• TABLE 8
  Genes associated with various functions

  		Direction of
  		expression
  Annotation	Probe	H vs P
  calcyphosine-like	Cfa.21214.1.S1_s_at	down
  ELKS/RAB6 interacting/CAST family member 2	Cfa.21214.1.S1_at	down
  glutamyl tRNA synthetase 2	Cfa.2057.1.A1_at	down
  Coiled-coil containing domain 3	Cfa.9084.1.A1_at	down
  chromosome 16 clone RP11-26P10	Cfa.3834.1.S1_at	down
  SAM domain- and HD domain-containing	CfaAffx.13689.1.S1_at	down
  protein 1
  AJ420591	Cfa.15196.1.A1_at	down
  family with sequence similarity 46, member A	CfaAffx.5194.1.S1_at	down
  CD1a antigen	Cfa.18390.1.S1_s_at	down
  epidermal dendritic cell marker (CD1a)	CfaAffx.17796.1.S1_at	down
  ANKYRIN MOTIF	CfaAffx.6104.1.S1_s_at	down
  RP11-549H3 on chromosome X	Cfa.9597.1.S1_at	down
  La ribonucleoprotein domain family, member 1	Cfa.14608.1.A1_at	down
  adenomatosis polyposis coli down-regulated 1	CfaAffx.28621.1.S1_at	down
  Chromosome 3 open reading frame 21	CfaAffx.20763.1.S1_at	down
  EGF-like module containing, mucin-like,	CfaAffx.28381.1.S1_s_at	down
  hormone receptor-like 1
  acyltransferase like 1	CfaAffx.14833.1.S1_at	down
  RP11-95J15 from 7	Cfa.6138.1.A1_at	down
  CD8 antigen, beta polypeptide 2	Cfa.21011.1.S1_at	down
  multimerin 1	CfaAffx.15515.1.S1_s_at	down
  none	Cfa.12500.1.A1_at	down
  Hypothetical protein FLJ21062	Cfa.1933.2.A1_at	down
  normal mucosa of esophagus specific 1	Cfa.11815.1.A1_at	down
  regulator of G-protein signalling 7	CfaAffx.24021.1.S1_s_at	down
  Islet cell auto-antigen 1	Cfa.11691.1.A1_at	down
  normal mucosa of esophagus specific 1 (NMES1),	CfaAffx.851.1.S1_s_at	down
  transcript variant 2
  none	Cfa.5989.1.A1_s_at	down
  eukaryotic translation initiation factor 2, subunit	Cfa.9060.1.A1_at	down
  3 gamma
  Serine/threonine kinase 17A	CfaAffx.21987.1.S1_at	down
  RP11-542F9 on chromosome 6	CfaAffx.21067.1.S1_at	up
  chromosome 20 open reading frame 172	CfaAffx.13625.1.S1_at	up
  RP11-111I12 on chromosome 1	CfaAffx.16431.1.S1_at	up
  BAT2 domain containing 1	Cfa.15064.1.S1_at	up
  Rho GTPase activating protein 11A	CfaAffx.13079.1.S1_s_at	up
  polo-like kinase 4	CfaAffx.6762.1.S1_s_at	up
  NADH dehydrogenase (ubiquinone) flavoprotein 3	CfaAffx.16432.1.S1_s_at	up
  3 BAC RP11-223L18	Cfa.3066.1.S1_at	up
  par-3 partitioning defective 3 homolog B	Cfa.12402.1.S1_a_at	up
  Hypothetical protein MGC24039	Cfa.19506.1.S1_at	up
  immunoglobulin mu heavy chain	CfaAffx.539.1.S1_x_at	up
  origin recognition complex, subunit 1-like	Cfa.8552.1.A1_s_at	up
  RP11-653G16 from 4	CfaAffx.15773.1.S1_at	up
  abnormal spindle-like microcephaly-associated	Cfa.103.1.A1_s_at	up
  protein
  Solute carrier family 22	Cfa.10558.2.S1_at	up
  BCSynL32 immunoglobulin lambda light chain	CfaAffx.346.1.S1_at	up
  Purinergic receptor P2Y, G-protein coupled 10	Cfa.1521.1.S1_at	up
  DEP domain containing 1	CfaAffx.31279.1.S1_at	up
  chromosome 17, clone RP11-160L11	Cfa.16355.1.S1_at	up
  Hypothetical protein LOC644115	Cfa.15220.2.A1_at	up
  isolate MRPS17P1 mitochondrial ribosomal	Cfa.12402.1.S1_s_at	up
  protein S17
  KIAA0101 (L5)	CfaAffx.26141.1.S1_s_at	up
  chromosome 13 open reading frame 3	CfaAffx.11656.1.S1_at	up
  SHC SH2-domain binding protein 1	CfaAffx.6499.1.S1_at	up
  CDC20 cell division cycle 20 homolog	CfaAffx.8850.1.S1_s_at	up
  Chromosome 14 open reading frame 32	CfaAffx.23135.1.S1_s_at	up
  3-oxoacyl-ACP synthase, mitochondrial	Cfa.10049.1.A1_s_at	up
  MAD2 mitotic arrest deficient-like 1	CfaAffx.25205.1.S1_s_at	up
  thioredoxin domain containing 5	Cfa.10753.1.A1_at	up
  Apla tubulin	Cfa.6991.1.A1_at	up
  none	CfaAffx.32.1.S1_at	up
  Melanin-concentrating hormone receptor 1	Cfa.6032.1.A1_at	up
  Aquaporin 7	Cfa.21549.1.S1_s_at	up
  cathepsin E	CfaAffx.15966.1.S1_at	up
  EF hand domain (C-terminal) containing 2	Cfa.1885.1.A1_at	up
  bone morphogenetic protein 6	Cfa.15702.1.S1_at	up
  hemoglobin, alpha 2	Cfa.3973.2.A1_s_at	up
  SH3-domain GRB2-like 3	Cfa.10644.1.A1_at	up
  Acidic nuclear phosphoprotein 32 family,	Cfa.31.1.S1_s_at	up
  member A
  none	CfaAffx.20953.1.S1_x_at	up
  Rh family, B glycoprotein	Cfa.13613.1.A1_at	up
  putative protein STRF8	CfaAffx.15063.1.S1_s_at	up
  fatty acid desaturase 1	Cfa.13257.1.A1_at	up
  Ligand dependent nuclear receptor corepressor-	Cfa.1476.1.A1_at	up
  like
  F-box only protein 2	CfaAffx.9335.1.S1_at	up
  Ring finger protein 152	Cfa.15414.1.A1_at	up
  immunoglobulin lambda constant 1	CfaAffx.22878.1.S1_at	up
  G-protein coupled receptor 158	Cfa.9162.1.A1_at	up
  Hypothetical protein MGC42105	CfaAffx.28387.1.S1_at	up

• Gene expression profiles from puppies fed Composition H and P are obtained and compared. Results indicate that 143 genes are differentially expressed between the study groups and, in general, their functions may be associated with cell assembly, cell cycle regulation, DNA replication and repair, cell compromise, arthritis and cancer. At a minimum of 1.5 fold change, 143 genes are differentially expressed in the two groups.
• Genes associated with arthritis/inflammation are down-regulated in puppies fed Composition H compared to puppies fed Composition P, which suggests reduced cartilage/joint damage in Prototype pups. A separate study performed also indicates that levels of bone alkaline phosphatase are lower in puppies fed composition H (data not shown). See Table 2.
• Genes associated with DNA fragmentation are down-regulated and genes associated with DNA processing control are up-regulated in puppies fed Composition H compared to puppies fed Composition P, which suggests reduced DNA damage and improved DNA protection in Prototype pups (also supported by elevated Vitamin E levels in blood, data not shown). See Table 3.
• Genes associated with cancer incidence are down-regulated and genes associated with tumor suppression are up-regulated in puppies fed Composition H compared to puppies fed Composition P, which suggests the possibility of reduced cancer susceptibility in these Prototype animals; see Table 4.
• Genes associated with cellular compromise are down-regulated and genes associated with cellular integrity are up-regulated in puppies fed Composition H compared to puppies fed Composition P, which suggests the possibility of reduced cell damage and enhanced cellular protection in these Prototype animals (also supported by elevated Vitamin E levels in blood, data not shown). See Table 5.
• Genes associated with disruption of cellular assembly are down-regulated and genes associated with proper cellular organization are up-regulated in puppies fed Composition H compared to puppies fed Composition P, which suggests improved cellular organization and function in Prototype pups. See Table 6.
• Genes associated with proper cell cycle regulation are up-regulated and genes associated with disruption of cell cycle control are down-regulated in puppies fed Composition H compared to puppies fed Composition P, which suggests proper control of cell cycle progression and cell survival. See Table 7.
• Thus, it is contemplated herein that the nutritional benefits of the compositions of the present invention as described herein may involve modification in gene expression which results in the enhancement of the development of a growing animal. In addition, feeding proper nutrients during early development may have a prophylatic effect and influence disease processes later in life, i.e., lessen the chance of disease in the animal, as the expression of genes associated with common diseases and disorders may be influenced due to the given nutritional compositions of the foods provided maternally and during early development.
Example 2
• An experiment is performed to determine the effects on gene expression in puppies fed Composition H vs. Composition P from weaning until one year of age.
• Dams utilized in this study are fed Composition P prior to, and during pregnancy. Following weaning, puppies are divided into two groups and provided with either Composition H or maintained on Composition P until one year old. Blood samples are then taken from the puppies and mRNA isolated according to conventional methods. Microarray assays are performed using the Affymetrix Canine-2 gene chip according to conventional methods.
• Results indicate that 99 genes are differentially expressed between the two study groups, and are presented in Tables 9-15. Of the genes identified, many are related to biological functions or pathways such as, e.g., immune activation, lipid metabolism, cardiovascular development, skeletal and muscular disorders, contraction and function and cell compromise and cancer.

• TABLE 9
  Genes associated with immune activation

  		Direction of
  		expression
  Annotation	Probe	H v. P
  lymphocyte antigen 6	CfaAffx.1839.1.S1_at	down
  complex
  Fc fragment of IgG, receptor,	Cfa.17806.2.S1_s_at	up
  transporter, alpha
  fibrinogen-like 2	Cfa.10303.1.S1_at	down
  CD1A antigen	Cfa.18390.1.S1_s_at	down
  complement factor D (adipsin)	Cfa.21381.1.S1_s_at	down
  CD163 antigen; macrophage-	Cfa.9647.1.A1_at	down
  associated antigen
  toll-like receptor 2	CfaAffx.13248.1.S1_s_at	down
  lysozyme (renal amyloidosis)	CfaAffx.1598.1.S1_s_at	down
  transcription elongation factor	Cfa.12580.1.S1_s_at	down
  A (SII), 3
  fibronectin 1	Cfa.3707.2.S1_at	down
  macrophage receptor with	Cfa.15713.1.A1_s_at	down
  collagenous structure
  bactericidal/permeability-	CfaAffx.14056.1.S1_s_at	down
  increasing protein
  T cell receptor alpha locus	Cfa.10333.1.A1_at	down
  immunoglobulin heavy	Cfa.4556.3.A1_a_at	down
  constant alpha 2
  nuclear factor I/B	Cfa.4487.1.S1_at	up

• TABLE 10
  Genes associated with Cancer formation

  		Direction of
  		expression
  Annotation	Probe	P vs C
  fibronectin 1	Cfa.3707.3.S1_s_at	down
  xanthine dehydrogenase	CfaAffx.9452.1.S1_s_at	down
  neuregulin 1	CfaAffx.10523.1.S1_s_at	down
  colony stimulating factor 1	CfaAffx.27899.1.S1_at	down
  receptor
  alanyl aminopeptidase	Cfa.3774.1.A1_s_at	down
  S100 calcium binding protein	CfaAffx.22128.1.S1_at	down
  dystroglycan 1	CfaAffx.17467.1.S1_at	up

• TABLE 11
  Genes associated with Lipid metabolism

  		Direction of
  		expression
  Annotation	Probe	H v. P
  Toll-like receptor 2	CfaAffx.13248.1.S1_s_at	Down
  cytochrome P450, family 1,	CfaAffx.10229.1.S1_at	Down
  subfamily B, polypeptide 1
  colony stimulating factor 1	CfaAffx.27899.1.S1_at	Down
  receptor
  phospholipase C, beta 1	Cfa.10853.1.A1_at	Down
  fibronectin 1	Cfa.3707.3.S1_s_at	Down
  neuregulin 1	CfaAffx.10523.1.S1_s_at	Down
  macrophage receptor with	Cfa.15713.1.A1_at	Down
  collagenous structure
  CD1a molecule	Cfa.18390.1.S1_s_at	Down

• TABLE 12
  Genes associated with Cardiovascular development

  		Direction of
  		expression
  Annotation	Probe	H v. P
  bactericidal/permeability-	CfaAffx.14056.1.S1_s_at	Down
  increasing protein
  fibronectin 1	Cfa.3707.3.S1_s_at	Down
  neuregulin 1	CfaAffx.10523.1.S1_s_at	Down
  xanthine dehydrogenase	CfaAffx.9452.1.S1_s_at	Down
  annexin A6	CfaAffx.27471.1.S1_s_at	Down
  colony stimulating factor 1	CfaAffx.27899.1.S1_at	Down
  receptor
  alanyl (membrane)	Cfa.3774.1.A1_s_at	Down
  aminopeptidase

• TABLE 13
  Genes associated with Skeletal/Muscular
  disorders and contraction/function

  		Direction of
  		expression
  Annotation	Probe	H v. P
  Skeletal/Muscular disorders
  Toll-like receptor 2	CfaAffx.13248.1.S1_s_at	down
  colony stimulating factor 1	CfaAffx.27899.1.S1_at	down
  receptor
  fibronectin 1	Cfa.3707.3.S1_s_at	down
  neuregulin 1	CfaAffx.10523.1.S1_s_at	down
  Muscle contraction/function
  exostoses	Cfa.11001.1.A1_at	up
  microfibrillar associated	CfaAffx.21449.1.S1_s_at	up
  protein 5
  myosin light polypeptide	Cfa.13192.1.S1_at	up
  kinase
  dystroglycan 1	CfaAffx.17467.1.S1_at	up
  Moloney leukemia virus	CfaAffx.1982.1.S1_s_at	up
  10-like 1

• TABLE 14
  Genes associated with Cellular Compromise

  		Direction of
  		expression
  Annotation	Probe	H v. P
  neuroregulin 1	CfaAffx.10523.1.S1_s_at	down
  fibronectin 1	Cfa.3707.3.S1_s_at	down
  macrophage receptor with	Cfa.15713.1.A1_at	down
  collagenous structure
  xanthine dehydrogenase	CfaAffx.9452.1.S1_s_at	down
  bactericidal permeability	CfaAffx.14056.1.S1_s_at	down
  increasing protein
  phospholipase C, beta 1	Cfa.10853.1.A1_at	down
  hemoglobin epsilon 1	CfaAffx.10240.1.S1_s_at	up

• TABLE 15
  Genes associated with various functions

  		Direction of
  		expression
  Annotation	Probe	H v. P
  CCR4-NOT transcription complex, subunit 10	Cfa.2403.1.A1_at	up
  ubiquitin carboxy-terminal hydrolase L5	Cfa.20277.1.S1_at	up
  SH3-domain GBR2-like 3	Cfa.10644.1.A1_at	up
  DEAH (Asp-Glu-Ala-His) box polypeptide 8	CfaAffx.22452.1.S1_s_at	up
  Signal-induced proliferation-associated 1 like 2	Cfa.14345.1.A1_at	up
  Cathepsin E	CfaAffx.15966.1.S1_at	up
  ephrin-B3	Cfa.15231.1.A1_at	up
  Fc fragment of IgG, receptor, transporter, alpha	Cfa.17806.2.S1_s_at	up
  Chromosome 20 open reading frame 172	Cfa.9662.1.A1_at	up
  Inositol(myo)-1(or 4) monophosphatase 2	Cfa.13029.1.A1_at	up
  Ferrochelatase (protoporphyria)	Cfa.365.3.A1_x_at	up
  G-protein coupled receptor 158	Cfa.9162.1.A1_at	up
  dual specificity phosphatase 19	CfaAffx.22249.1.S1_at	up
  Ring finger protein 152	Cfa.15414.1.A1_at	up
  Chromosome 12 open reading frame 49	Cfa.11298.1.S1_at	up
  hemoglobin, epsilon 1	CfaAffx.10240.1.S1_s_at	up
  Crystallin lambda 1	Cfa.4354.1.S1_a_at	up
  Sorting nexin 6	Cfa.10261.1.S1_at	up
  microfibrillar associated protein 5	CfaAffx.21449.1.S1_s_at	up
  coiled-coil domain containing 46	CfaAffx.17557.1.S1_s_at	up
  Nuclear factor I/B	Cfa.4487.1.S1_at	up
  carboxypeptidase A3	CfaAffx.13076.1.S1_at	up
  chromosome 18, clone RP11-396D4	CfaAffx.26602.1.S1_at	up
  coxsackie and adenovirus receptor protein	CfaAffx.13148.1.S1_at	up
  WW domain containing oxidoreductase, transcript	Cfa.9201.1.A1_at	up
  variant 4
  EH domain binding protein 1-like 1	Cfa.17641.1.S1_s_at	Down
  RP4-760G15 on chromosome 11p13	Cfa.17214.1.S1_at	Down
  phospholipase C beta 1 (phosphoinositide-Specific)	Cfa.10853.1.A1_at	Down
  cathepsin L	CfaAffx.2868.1.S1_at	Down
  Transcription elongation factor A, 1	Cfa.12580.1.S1_s_at	Down
  glypican 6	Cfa.9523.1.A1_at	Down
  Hypothetical protein FLJ21062	Cfa.1933.2.A1_at	Down
  G-protein coupled receptor 101	CfaAffx.12632.1.S1_at	Down
  Leucine-rich repeat kinase 2	CfaAffx.15613.1.S1_s_at	Down
  Six transmembrane epithelial anitgen of the	Cfa.9430.1.A1_at	Down
  prostate 2
  KIAA1074 protein	Cfa.12143.1.A1_at	down
  LOC284395	Cfa.4802.1.S1_at	down
  elastin microfibril interfacer 2	CfaAffx.28185.1.S1_at	down
  Sulfatase 2	CfaAffx.17034.1.S1_s_at	down
  IBR domain containing 2	Cfa.1882.1.A1_at	down
  Leucyl/cystinyl aminopeptidase	CfaAffx.12483.1.S1_s_at	down
  acyltransferase like 1	CfaAffx.14833.1.S1_at	down
  NAD kinase	CfaAffx.29324.1.S1_at	down
  Immunoglobulin heavy constant alpha 2	Cfa.4556.3.A1_x_at	down
  transcription factor EC (TFEC), transcript	Cfa.1175.1.A1_s_at	down
  variant 2
  Acyl-CoA synthetase short-chain family	CfaAffx.12483.1.S1_at	down
  member 1
  Syntaxin binding protein 6	Cfa.9054.1.A1_at	down
  Opioid growth factor receptor-like 1	Cfa.583.1.S1_at	down
  None	Cfa.10106.1.A1_at	down
  None	Cfa.4556.3.A1_s_at	down
  ELK/RAB6-interacting/CAST family member 2	Cfa.21214.1.S1_at	down
  adipsin/complement factor D precursor	Cfa.21381.1.S1_s_at	down
  Hypothetical protein FLJ22662	CfaAffx.20271.1.S1_at	down
  solute carrier family 2 (facilitated glucose	Cfa.7132.1.A1_at	down
  transporter), member 9
  Homogentisate 1,2 dioxygenase	CfaAffx.9076.1.S1_s_at	down
  serpin peptidase inhibitor, clade B (ovalbumin),	CfaAffx.1043.1.S1_s_at	down
  member 10
  None	Cfa.13203.1.S1_at	down
  Fibrinogen-like 2	CfaAffx.7369.1.S1_s_at	down
  None	Cfa.12500.1.A1_at	down
  None	Cfa.4556.2.S1_s_at	down
  None	Cfa.4555.1.S1_s_at	down
  None	Cfa.280.1.S1_at	down
  Lymphocyte antigen 6	CfaAffx.1839.1.S1_at	down
  Neuronal PAS domain protein 3	Cfa.12905.1.A1_a_at	down

• Gene expression profiles from puppies fed Composition H or P from weaning to one year of age are obtained and compared. Microarray data indicate that, at a minimum of 1.5 fold change, 99 genes are differentially expressed in the two study groups.
• Genes associated with immune activation are down-regulated in puppies fed Composition H when compared to puppies fed Composition P, which suggests improved immune system function (Table 9).
• Genes associated with lipid metabolism are down-regulated in puppies fed Composition H when compared to puppies fed Composition P, which suggests reduced lipid processing (Table 11).
• Genes associated with cardiovascular development are also down-regulated in puppies fed Composition H when compared to puppies fed Composition P, which suggests enhanced cardiovascular health (Table 12).
• Genes associated with skeletal muscular disorders are down-regulated and genes associated with muscle contraction/function are up-regulated in puppies fed Composition H when compared to puppies fed Composition P, which suggests reduced skeletal disorder risk and improved muscle contraction (Table 13).
• Genes associated with cellular compromise are down-regulated in puppies fed Composition H when compared to puppies fed Composition P, which suggests reduced cellular damage (Table 14).
• Genes known to have an association with cancer are down-regulated in puppies fed Composition H when compared to puppies fed Composition P, which may suggest reduced cancer susceptibility. (Table 10).
• As discussed above, genetic data such as these indicate that the nutritional benefits of the compositions of the present invention include the beneficial modification of gene expression in the animal such that there is an overall enhancement in the development of the animal. In addition, the beneficial modification of gene expression may also result in a decrease in the incidence of disease in the animal due to an inhibition in expression of disease related genes and/or an increase in the expression of genes which play a role in disease prevention.

Claims (23)

1. A pet food composition comprising:

about 5 to about 70% protein,

about 0.5 to about 1.6% methionine,

about 50 to about 200 ppm manganese,

about 0.1 to about 0.5% DHA.

about 0.1 to about 0.7% EPA.

about 1200 to about 7500 ppm choline,

about 1000 to about 2000 ppm taurine,

about 2.5 to about 6% linoleic acid,

about 1 to about 3% total n-3 fatty acids,

about 50 to about 1200 IU/kg vitamin E.

about 50 to about 500 ppm vitamin C,

about 50 to about 500 ppm carnitine, and

about 2.5 to about 7 g lysine/1000 kcal.

2. The composition of claim 1 comprising:

0 to about 90% by weight of carbohydrates:

about 20% to about 60% by weight of protein;

about 2% to about 50% by weight of fat;

about 0.1% to about 20% by weight of total dietary fiber; and

0 to about 15% by weight of vitamins, minerals, and other nutrients

3. The composition of claim 1 comprising about 0.1% to about 0.4% DHA.

4. The composition of claim 1 comprising about 100 ppm to about 500 ppm carnitine.

5. The composition of claim 1 comprising about 2.5 g/1000 kcal to about 7 a/1000 kcal lysine.

6. The composition of claim 1 comprising about 0.1% to about 0.6% EPA.

7. The composition of claim 1 comprising about 50 ppm to about 150 ppm manganese.

8. The composition of claim 1 comprising about 0.8% to about 1.6% methionine.

9. A method to regulate gene expression in a canine comprising administering to the canine or to the mother of the canine while the canine is in utero a composition according to claim 1.

10. The method of claim 9 wherein the canine is a puppy.

11. The method of claim 9 wherein the canine is born of a dam fed the composition during pregnancy.

12. The method of claim 10 wherein the puppy is in utero.

13. The method of claim 11 wherein the dam is fed the composition prior to pregnancy.

14. The method of claim 11 wherein the dam is fed the composition for a majority of the pregnancy duration.

15. The method of claim 11 wherein the dam is fed the composition prior to and during pregnancy.

16. The method of claim 10 wherein the puppy is fed the composition prior to weaning.

17. The method of claim 10 wherein the puppy is fed the composition post weaning.

18. The method of claim 17 wherein the puppy is fed the composition substantially exclusively.

19. The method of claim 9 wherein an effective amount of the composition is administered to the canine.

20. The method claim 9 wherein the composition is administered to the canine for an effective amount of time.

21. The method of claim 20 wherein the composition is administered to the canine for at least one year post partum or one year post weaning.

22. The method claim 9 wherein the gene is selected from those listed in Tables 2-15.

23. A method to cause a beneficial modification in the expression of any one or more genes provided in Tables 2-5 in an animal, for any one or more biological conditions, pathways or disease states described in Tables 2-15, comprising administering an effective amount of a composition according claim 1 to the animal, either directly to the animal or to the dam of the animal while the animal is in utero.